Patents by Inventor John Fenyu JIN

John Fenyu JIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-HER2/ANTI-CD47 MOLECULES AND USES THEREOF
    Publication number: 20250215109
    Abstract: Provided herein are anti-CD47/anti-HER2 polypeptide complexes, nucleic acid molecules encoding the variable domains of the polypeptide complexes, expression vectors and host cells used for the expression of the polypeptide complexes. The disclosure further provides methods for producing the polypeptide complexes and uses thereof.
    Type: Application
    Filed: March 16, 2023
    Publication date: July 3, 2025
    Inventors: Siwei NIE, Jiaxiang SHAO, Qin MEI, Fagen HU, Jianqing XU, Shuang WANG, Jijie GU, Yuhong SHEN, Zhijian CHEN, John Fenyu JIN, Haopeng RUI
  • PYRIMIDOHETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF
    Publication number: 20250154151
    Abstract: A class of pyrimidoheterocyclic compounds, and specifically disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 23, 2024
    Publication date: May 15, 2025
    Inventors: Yang ZHANG, Wentao WU, Jing ZHANG, Jikui SUN, Yangyang XU, Zhijian CHEN, John Fenyu JIN, Shuhui CHEN
  • Pyrimidoheterocyclic compounds and application thereof
    Patent number: 12162880
    Abstract: A class of pyrimidoheterocyclic compounds, and specifically disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: December 10, 2024
    Assignee: D3 BIO (WUXI) CO., LTD.
    Inventors: Yang Zhang, Wentao Wu, Jing Zhang, Jikui Sun, Yangyang Xu, Zhijian Chen, John Fenyu Jin, Shuhui Chen
  • Pyrimidoheterocyclic compounds and application thereof
    Patent number: 12012404
    Abstract: A class of pyrimidoheterocyclic compounds, and specifically disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 22, 2023
    Date of Patent: June 18, 2024
    Assignee: D3 Bio (Wuxi) Co., Ltd.
    Inventors: Yang Zhang, Wentao Wu, Jing Zhang, Jikui Sun, Yangyang Xu, Zhijian Chen, John Fenyu Jin, Shuhui Chen
  • PYRIMIDOHETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF
    Publication number: 20240116934
    Abstract: A class of pyrimidoheterocyclic compounds, and specifically disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 22, 2023
    Publication date: April 11, 2024
    Inventors: Yang ZHANG, Wentao WU, Jing ZHANG, Jikui SUN, Yangyang XU, Zhijian CHEN, John Fenyu JIN, Shuhui CHEN
  • PYRIMIDOHETEROCYCLIC COMPOUNDS AND APPLICATION THEREOF
    Publication number: 20230151004
    Abstract: A class of pyrimidoheterocyclic compounds, and specifically disclosed is a compound represented by formula (III) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 11, 2021
    Publication date: May 18, 2023
    Inventors: Yang ZHANG, Wentao WU, Jing ZHANG, Jikui SUN, Yangyang XU, Zhijian CHEN, John Fenyu JIN, Shuhui CHEN
  • Inhibitor of metadherin expression
    Publication number: 20230067620
    Abstract: The present invention refers to an inhibitor consisting of an oligonucleotide comprising 12 to 25 nucleotides, wherein at least one of the nucleotides is modified, and the oligonucleotide hybridizes with a nucleic acid sequence of MTDH of SEQ ID NO.1 (human mRNA), SEQ ID NO.2 (human pre-mRNA), SEQ ID NO.223 (mouse mRNA) and/or SEQ ID NO.224 (mouse pre-mRNA), wherein the oligonucleotide inhibits at least 50% of the MTDH expression. The invention is further directed to a pharmaceutical composition comprising such oligonucleotide.
    Type: Application
    Filed: September 14, 2020
    Publication date: March 2, 2023
    Inventors: Frank JASCHINSKI, Richard KLAR, Sven MICHEL, John Fenyu JIN